Radar · Life Sciences in San Diego
Best Life Sciences Companies in San Diego, United States
The 847 best Life Sciences companies in San Diego, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Halozyme.
By Riya SenguptaFinancials
847companies tracked
$29.3Bdisclosed funding
2unicorns
479have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × SAN DIEGO
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
164companies analysed
83%cloud-native stacks
2025funding peak (by rounds)
7unicorns
2016median founding year
270kcombined LinkedIn audience
39%of audience held by top 3
8companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in San Diego
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Element Biosciences 🦄 Developer of benchtop DNA sequencer for research applications 84Innovation top 10%Patents top 13%Funding top 16%Moat top 22% All 11 signals ▾Innovationtop 10% Patentstop 13% Fundingtop 16% Moattop 22% Markettop 35% Growthtop 35% Talenttop 38% Producttop 41% Techtop 45% Globalbottom 47% Newsbottom 24% Innovation: 554 patents (top 4% of patent-holders) · 469 filings since 2022 vs 85 in 2017-21 Patents: 554 patents matched (strict assignee match) · 469 filings since 2022 vs 85 in 2017-21 rank vs industry peers · Fliar Intelligence Index 84/100 | $678M | 23 mo ago | Series D | 318 | Michael Previte CTO | 554 patents Advanced optical flow cells, reagents, and data processing for next‑gen DNA sequencing | 1 job opening |
| 2 | Mirador Developer of therapeutics for immune-mediated inflammatory and fibrotic diseases 50Funding top 15%Growth top 35%Moat top 42%Tech top 44% All 9 signals ▾Fundingtop 15% Growthtop 35% Moattop 42% Techtop 44% Producttop 49% Talentbottom 49% Newsbottom 38% Globalbottom 36% Marketbottom 32% Funding: Raised $480M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 50/100 | $480M | 5 mo ago | Series B | — | Mark McKenna Founder & CEO | — | — |
| 3 | Human Longevity Provider of precision medicine, preventative health assessments, and longevity care | $409M | 21 mo ago | Series B | 85 | J Venter Co-Founder & CEO | 71 patents AI-driven multi‑omic analytics for disease risk assessment, diagnosis, and genomic trait prediction | 1 launch · 1 partnership |
| 4 | Sorrento Therapeutics Developer of immuno therapeutics for cancer, inflammation, and autoimmune diseases 67Funding top 20%Patents top 20%Market top 26%Moat top 30% All 12 signals ▾Fundingtop 20% Patentstop 20% Markettop 26% Moattop 30% Innovationtop 32% Growthtop 45% Fin. healthtop 45% Partnerstop 45% Talentbottom 49% Globalbottom 44% Techbottom 31% Newsbottom 27% Funding: Raised $282M across 17 rounds · 17 rounds over 17 yrs (1.0/yr) Patents: 1,073 patents matched (strict assignee match) · 312 filings since 2022 vs 587 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $282M | 14 mo ago | Public | 949 | Henry Ji Co-Founder & CEO | 1,073 patents Patents concentrated in health & consumer products | — |
| 5 | BlossomHill Therapeutics Provider of the drug for the treatment of oncology and autoimmune disorders 55Funding top 20%Patents top 21%Innovation top 23%Moat top 26% All 7 signals ▾Fundingtop 20% Patentstop 21% Innovationtop 23% Moattop 26% Newsbottom 42% Globalbottom 42% Marketbottom 34% Funding: Raised $260M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) Patents: 133 patents matched (strict assignee match) · 133 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $260M | 6 mo ago | Series B | 14 | — | 133 patents Patents concentrated in chemistry & materials | 3 job openings |
| 6 | Autobahn Therapeutics Provider of therapeutics for CNS disorders by the regenerative medicine | $228M | 23 mo ago | Series C | 23 | Kevin Finney Chairman and CEO | — | — |
| 7 | Aspen Neuroscience Provider of genomic-based personalised pluripotent stem cell therapy 64Funding top 17%Patents top 23%Moat top 28%Innovation top 33% All 10 signals ▾Fundingtop 17% Patentstop 23% Moattop 28% Innovationtop 33% Growthtop 35% Newstop 45% Marketbottom 49% Talentbottom 49% Techbottom 46% Globalbottom 45% Funding: Raised $224M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) Patents: 57 patents matched (strict assignee match) · 51 filings since 2022 vs 6 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $224M | 6 mo ago | Series C | 94 | Damien Mcdevitt President | 57 patents Patents concentrated in computing, sensing & instrumentation | — |
| 8 | Avenzo Therapeutics Developer of therapeutics for cancer treatment | $223M | 9 mo ago | Series B | 8 | Mohammad Hirmand Co-Founder & Chief Medical Officer | — | 1 job opening |
| 9 | Iambic Therapeutics Provider of AI-driven drug discovery platform for the treatment of cancer 60Funding top 15%AI top 26%Moat top 31%Talent top 38% All 9 signals ▾Fundingtop 15% AItop 26% Moattop 31% Talenttop 38% Growthtop 45% Marketbottom 43% Newsbottom 43% Techbottom 40% Globalbottom 39% Funding: Raised $206M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) AI: Classified as an AI company · Product described with: ai driven, ai-driven rank vs industry peers · Fliar Intelligence Index 60/100 | $206M | 2 mo ago | Series C | 50 | Fred Manby Co-Founder & CTO | — | — |
| 10 | Candid Therapeutics Developer of therapeutics for autoimmune diseases 40Funding top 17%Growth top 38%News top 48%Moat top 48% All 8 signals ▾Fundingtop 17% Growthtop 38% Newstop 48% Moattop 48% Talentbottom 49% Techbottom 38% Globalbottom 38% Marketbottom 32% Funding: Raised $206M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $206M | 3 mo ago | Acquired | — | Ken Song CEO | — | — |
| 11 | MEI Pharma Developer of targeted therapies for the treatment of cancer | $204M | 11 mo ago | Public | 46 46 → 110 (+139%) | — | 329 patents Novel CDK9 inhibitor polymorphs and oncology combination therapies (PI3K/PD‑1). | — |
| 12 | Solve Therapeutics Developer of antibody-based therapies targeting tumor-specific antigens for cancer treatment 55Funding top 16%Moat top 40%Global top 45%Market bottom 49% All 5 signals ▾Fundingtop 16% Moattop 40% Globaltop 45% Marketbottom 49% Talentbottom 49% Funding: Raised $195M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Moat: Soonicorn · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 55/100 | $195M | 7 mo ago | Series D | — | Dave Johnson Founder & CEO | — | — |
| 13 | Biolinq Provider of a wearable biosensor platform for diabetes monitoring 67Innovation top 13%Funding top 17%Patents top 17%Moat top 26% All 10 signals ▾Innovationtop 13% Fundingtop 17% Patentstop 17% Moattop 26% Talenttop 38% Growthtop 45% Marketbottom 45% Globalbottom 43% Techbottom 39% Newsbottom 18% Innovation: 189 patents (top 11% of patent-holders) · 161 filings since 2022 vs 28 in 2017-21 Funding: Raised $175M across 15 rounds · 15 rounds over 12 yrs (1.2/yr) rank vs industry peers · Fliar Intelligence Index 67/100 | $175M | 15 mo ago | Series C | 91 | Jared Tangney Co-Founder | 189 patents Minimally invasive microneedle-based continuous biosensing for interstitial fluid analytes | — |
| 14 | Expedition Therapeutics Developer of treatments targeting inflammatory and respiratory diseases for patient care | $165M | 8 mo ago | Series A | — | Yi Larson CEO & President | — | — |
| 15 | Plexium Precision medicine company pioneering targeted protein degradation therapeutics | $165M | 11 mo ago | Series B | 81 | Andrew MacConnell Co-Founder | 121 patents Epigenetic protein degraders and oligonucleotide‑encoded small‑molecule discovery platforms | — |
| 16 | RayThera Developer of small molecule therapies for unmet needs in immunology | $110M | 14 mo ago | Series A | — | Gene Hung Co-Founder & CSO | 12 patents Peptide-based modulators targeting Jak2 V617F, TNF‑α, CCR4, and STAT6 signaling | — |
| 17 | Neomorph Developer of therapeutic solutions for the treatment of multiple diseases based on protein degradation… 53Funding top 23%Moat top 28%Talent top 28%Patents top 39% All 10 signals ▾Fundingtop 23% Moattop 28% Talenttop 28% Patentstop 39% Innovationtop 44% Partnerstop 45% Marketbottom 48% Techbottom 42% Globalbottom 33% Newsbottom 20% Funding: Raised $109M across 2 rounds · 2 rounds over 6 yrs (0.3/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 25 patents rank vs industry peers · Fliar Intelligence Index 53/100 | $109M | 2 mo ago | Series B | 54 | Philip Chamberlain Co-Founder & CEO | 25 patents Novel substituted piperidine-imide heterocycles for pharmaceutical active ingredient development | 5 job openings |
| 18 | Debut Provider and manufacturer of enzymes for biotherapeutic creation and modification 35Funding top 21%Moat top 31%News top 34%Tech bottom 49% All 7 signals ▾Fundingtop 21% Moattop 31% Newstop 34% Techbottom 49% Talentbottom 48% Globalbottom 45% Marketbottom 31% Funding: Raised $106M across 7 rounds · 7 rounds over 6 yrs (1.2/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 35/100 | $106M | 9 mo ago | Series B | 18 | Gregory Weiss Co-Founder | — | 1 partnership |
| 19 | Evofem Developer of sexual and reproductive health therapeutics 50Funding top 24%Product top 30%Moat top 38%Patents top 43% All 12 signals ▾Fundingtop 24% Producttop 30% Moattop 38% Patentstop 43% Fin. healthtop 46% Innovationtop 48% Markettop 49% Growthbottom 49% Talentbottom 49% Techbottom 43% Newsbottom 41% Globalbottom 40% Funding: Raised $100M across 15 rounds · 15 rounds over 17 yrs (0.9/yr) Product: 1 distinct product line · Company stage: Public rank vs industry peers · Fliar Intelligence Index 50/100 | $100M | 11 mo ago | Public | 126 | Saundra Pelletier CEO ► Phexxi ► Solosec | 60 patents Vaginal film drug delivery systems for contraception, STI prevention, and antimicrobial microbicides | 1 partnership |
| 20 | CalciMedica Developer of CRAC channel inhibitor drugs for inflammatory diseases | $87M | 14 mo ago | Public | 11 | — | 271 patents CRAC channel inhibitor drugs for inflammatory lung and pancreatic disorders | — |
| 21 | Cidara Therapeutics Developer of novel anti-infectives for infectious diseases (bacterial and fungal) | $78M | 18 mo ago | Acquired | 90 90 → 48 (-47%) | Jeff Stein CEO | 275 patents Antibody‑drug conjugates and biologics targeting viral and cancer pathways. | — |
| 22 | Tr1X Developer of T cell-based products to treat autoimmune and inflammatory diseases | $75M | 14 mo ago | Series A | 7 | David Vries Co-Founder | 35 patents IL-10‑secreting CD4+ CAR‑T cell immunotherapies for enhanced immune regulation | — |
| 23 | Trefoil Therapeutics Developer protein engineering drugs to treat corneal endothelial diseases | $73M | 13 mo ago | Series A | 10 | Michael Blaber Co-Founder | — | — |
| 24 | ClearNote Health Developer of non-invasive cancer detection methods 40Moat top 22%Funding top 36%Market top 50%Talent bottom 49% All 5 signals ▾Moattop 22% Fundingtop 36% Markettop 50% Talentbottom 49% Globalbottom 36% Moat: Editorial + unicorn rating 8/10 · Soonicorn Funding: Raised $70.0M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $70M | 0 mo ago | Series D | 45 | Dave Mullarkey Chief Executive Officer | — | — |
| 25 | Actio Biosciences Developer of genetics-led therapies targeting shared biology between rare, common diseases | $55M | 12 mo ago | Series B | 21 | David Goldstein Co-Founder & CEO | — | 1 job opening |
| 26 | Primmune Therapeutics Developer of immunotherapies for treating cancer 42Funding top 21%Talent top 28%Product top 35%Innovation top 38% All 8 signals ▾Fundingtop 21% Talenttop 28% Producttop 35% Innovationtop 38% Moattop 39% Techbottom 40% Globalbottom 36% Marketbottom 26% Funding: Raised $46.8M across 8 rounds · 8 rounds over 6 yrs (1.3/yr) Talent: Analyst team rating 4/5 · 4 named leaders on record rank vs industry peers · Fliar Intelligence Index 42/100 | $47M | 4 mo ago | Series B | 9 | Stephen Webber Co-Founder | — | — |
| 27 | Electronic Bio Provider of nanotech-based DNA sequencing solutions 10Funding top 37%Talent bottom 45%Global bottom 29%Market bottom 24% All 5 signals ▾Fundingtop 37% Talentbottom 45% Globalbottom 29% Marketbottom 24% Techbottom 15% Funding: Raised $40.7M across 49 rounds · 49 rounds over 19 yrs (2.6/yr) Talent: 1 named leader on record rank vs industry peers · Fliar Intelligence Index 10/100 | $41M | 12 mo ago | Funding Raised | 15 | Eric Ervin President and CEO | — | — |
| 28 | Artelo Biosciences Modifying lipid-signaling pathways to improve cancer treatments 53Funding top 17%Growth top 20%News top 23%Product top 24% All 9 signals ▾Fundingtop 17% Growthtop 20% Newstop 23% Producttop 24% Innovationtop 43% Talenttop 46% Techbottom 46% Globalbottom 38% Marketbottom 24% Funding: Raised $39.9M across 13 rounds · 13 rounds over 8 yrs (1.6/yr) Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $40M | 2 mo ago | Public | 7 | Greg Gorgas CEO & President | — | 1 partnership |
| 29 | Daré Bioscience Developer of non-hormonal pharmaceutical products for female contraceptives 50Funding top 27%Product top 28%Growth top 37%Innovation top 38% All 11 signals ▾Fundingtop 27% Producttop 28% Growthtop 37% Innovationtop 38% Techtop 40% Moattop 48% Talentbottom 49% Newsbottom 45% Fin. healthbottom 43% Marketbottom 33% Globalbottom 32% Funding: Raised $39.7M across 17 rounds · 17 rounds over 9 yrs (1.9/yr) Product: 3 distinct product lines · 1 published app (300 installs) rank vs industry peers · Fliar Intelligence Index 50/100 | $40M | 6 mo ago | Public | 30 30 → 27 (-10%) | Sabrina Johnson President and CEO | — | 4 launchs |
| 30 | Equillium Developer of therapies for treating autoimmune and inflammatory disorders | $30M | 10 mo ago | Public | 36 36 → 38 (+6%) | Daniel Bradbury Co-Founder & CEO | 33 patents Immunotherapy antibodies targeting CD6 for autoimmune and inflammatory disease treatment | — |
| 31 | TriLink BioTech Developer of nucleic acid and mRNA products for research applications | $29M | 15 mo ago | Acquired | 348 | — | — | 3 launchs · 1 expansion · 1 award |
| 32 | Alume Biosciences Developer of a nerve illuminating technology | $28M | 2 mo ago | Series B | 7 | Mike Whitney Scientific Founder and VP of Discovery | — | — |
| 33 | Direct Electron Developer of cameras for electron microscopy 57Innovation top 20%Growth top 35%Tech top 41%Funding top 42% All 8 signals ▾Innovationtop 20% Growthtop 35% Techtop 41% Fundingtop 42% Producttop 46% Talentbottom 45% Globalbottom 29% Marketbottom 23% Innovation: 11 product lines Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 57/100 | $25M | 12 mo ago | Funding Raised | 13 | Rob Bilhorn Founder & President | — | 1 launch |
| 34 | Epigen Biosciences Provider of drug discovery translation services | $24M | 13 mo ago | Funding Raised | 13 | — | 57 patents Small-molecule heterocyclic kinase inhibitors for S6K-mediated disease therapies | — |
| 35 | Condor Software-based financial management platform for clinical industries 29Funding top 27%News top 29%Talent top 38%Tech top 45% All 9 signals ▾Fundingtop 27% Newstop 29% Talenttop 38% Techtop 45% Moattop 48% Innovationbottom 46% Productbottom 45% Globalbottom 32% Marketbottom 21% Funding: Raised $24.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) News: 3 BI events in 12 mo (of 5 tracked, 3 types) · +200% YoY rank vs industry peers · Fliar Intelligence Index 29/100 | $24M | 3 mo ago | Series A | 8 | John Sammataro Co-Founder | — | — |
| 36 | Model Medicines Developer of AI-based drug discovery platform | $20M | 7 mo ago | Series A | 26 | Daniel Haders II Chief Executive Officer | 18 patents Antiviral therapeutics targeting DNA/RNA viruses, including SARS‑CoV‑2, using pipendoxifene. | — |
| 37 | Sinopia Biosciences Data-driven drug discovery using multi-omics, AI, and disease models 13Funding top 28%AI top 45%Global bottom 29%Tech bottom 26% All 5 signals ▾Fundingtop 28% AItop 45% Globalbottom 29% Techbottom 26% Marketbottom 16% Funding: Raised $19.4M across 13 rounds · 13 rounds over 5 yrs (2.6/yr) AI: Product described with: machine learning rank vs industry peers · Fliar Intelligence Index 13/100 | $19M | 2 mo ago | Funding Raised | 4 | — | — | — |
| 38 | Paulex Bio Developer of therapeutics for diabetes treatment | $19M | 6 mo ago | Series B | — | Miguel Sanjuan CEO & Founder | — | — |
| 39 | SelectION Provider of screening and development platform for drugs 11Funding top 36%Talent bottom 49%Global bottom 37%Market bottom 17% All 4 signals ▾Fundingtop 36% Talentbottom 49% Globalbottom 37% Marketbottom 17% Funding: Raised $15.9M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 11/100 | $16M | 9 mo ago | Series A | 2 | Andreas Klostermann Founder & CSO | — | — |
| 40 | Dermata Therapeutics Developer of therapeutics to treat a variety of dermatologic and ophthalmologic diseases | $16M | 5 mo ago | Public | 8 | Gerry Proehl President & CEO | — | — |
| 41 | Novoron Bioscience Developer of therapeutics for neurological diseases 22Funding top 34%Innovation top 38%Product top 48%Global bottom 32% All 6 signals ▾Fundingtop 34% Innovationtop 38% Producttop 48% Globalbottom 32% Marketbottom 25% Techbottom 24% Funding: Raised $15.1M across 10 rounds · 10 rounds over 11 yrs (0.9/yr) Innovation: 3 product lines rank vs industry peers · Fliar Intelligence Index 22/100 | $15M | 3 mo ago | Seed | 11 11 → 16 (+45%) | — | — | 1 job opening · 1 partnership |
| 42 | Proviso Medical Developer of endovascular devices integrated with Sonic Lumen Tomography for cardiac diseases | $15M | 9 mo ago | Series A | 20 | S Ryan Founder & CEO | — | — |
| 43 | Navega Therapeutics Developer of gene therapy products for chronic pain management | $15M | 13 mo ago | Funding Raised | 10 | Prashant Mali Co-Founder | — | — |
| 44 | RyboDyn Developer of immunotherapies for the treatment of cancer 21Talent top 28%Funding top 37%Global bottom 48%Market bottom 15% All 4 signals ▾Talenttop 28% Fundingtop 37% Globalbottom 48% Marketbottom 15% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $14.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 21/100 | $14M | 2 mo ago | Seed | 3 | Kerry Wilson Co-Founder | — | — |
| 45 | Eclipse Bio Developer of cell-free immunoassay | $14M | 7 mo ago | Series A | 14 | Eric Van Nostrand Co-Founder | — | 1 award |
| 46 | Starlight Cardiovascular Manufacturer of devices for treatment of pediatric congenital heart defects | $9M | 12 mo ago | Series A | 8 | Tom Duerig Co-Founder | 17 patents Minimally invasive cardiovascular implant delivery and variable-diameter stent technologies. | 1 job opening |
| 47 | Spinogenix Developer of therapeutics for brain injury and neurodegenerative diseases | $9M | 6 mo ago | Series B | 7 | Stella Sarraf Founder & CEO | 58 patents Small-molecule spinogenesis promoters for ophthalmic, metabolic, and neurodegenerative therapies | 1 launch |
| 48 | AvantGen Antibody discovery and engineering company advancing antibody drugs for scientific partners | $8M | 10 mo ago | Funding Raised | 11 | — | 16 patents Therapeutic peptide ligands targeting immune receptors and SARS‑CoV‑2 viral proteins | — |
| 49 | Qureator Developer of micro physiological systems for drug discovery | $7M | 5 mo ago | Series A | 22 | Kyu Baek CEO | 7 patents Microfluidic chip architectures enabling rounded corners and perfusable vascular networks for organ‑on‑chip applications. | 1 job opening |
| 50 | Tega Therapeutics Glycoscience company developing heparan sulfate therapies and enzyme replacement therapy | $4M | 6 mo ago | Funding Raised | 7 | — | — | — |
Top 12 Life Sciences companies in San Diego
#1
Series C · San Diego, California · founded 2019 · 50 employees$206.2Mraised▾
Series C · San Diego, California · founded 2019 · 50 employees
Provider of AI-driven drug discovery platform for the treatment of cancer. It offers an AI driven discovery platform and has discovered two candidates known as IAM-H1, a highly selective and brain penetrant inhibitor of HER2 and its oncogenic mutants, and IAM-C1 a potential first-in-class selective dual CDK2/4 inhibitor to address unmet needs in terms of therapeutic window and treatment resistance in cell cycle driven cancers.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 15%AI
top 26%Moat
top 31%Talent
top 38%Growth
top 45%Market
bottom 43%Funding: Raised $206M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) · Last round Series C (Apr 2026)
AI: Classified as an AI company · Product described with: ai driven, ai-driven
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Funding rounds
- Apr 2026Series C$27.8M
- Nov 2025Series C$100M
- Apr 2024Series B$50M
- Oct 2023Series B$103.2M
Founders & team
Investors
Ascenta Capital, Abingworth, Nvidia, Illumina Ventures, Shanda, Catalio Capital Management
Tech stack
Apple Icloud MailCloudflareDocusignGoogle Font ApiGoogle Hosted LibrariesHsts
#2
Series B · San Diego, California · founded 2023$480Mraised▾
Series B · San Diego, California · founded 2023
Developer of therapeutics for immune-mediated inflammatory and fibrotic diseases. The company’s Mirador360 precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 15%Growth
top 35%Moat
top 42%Tech
top 44%Product
top 49%Talent
bottom 49%Funding: Raised $480M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series B (Jan 2026)
Growth: Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 4/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 119 LinkedIn followers
Funding rounds
- Jan 2026Series B$250M
- Feb 2024Series A$400M
- Dec 2023Seed$80M
Founders & team
Investors
Arch Venture Partners, Orbimed, Fairmount Partners, Sanofi, Point72 Ventures, Farallon Capital Management
Tech stack
AddtoanyAmazon CloudfrontAmazon Web ServicesApache Http ServerApple Icloud MailCookiebot
#3
Acquired · San Diego, California · founded 2024$206.2Mraised▾
Acquired · San Diego, California · founded 2024
Developer of therapeutics for autoimmune diseases. It focuses on identifying and targeting specific pathways to develop therapies which include CND106 a bispecific antibody that targets and eliminate later stage B-cellsf or autoantibody disease treatment, CND261 targets a broad range of B-cell subtypes for autoimmune diseases.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 17%Growth
top 38%News
top 48%Moat
top 48%Talent
bottom 49%Tech
bottom 38%Funding: Raised $206M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series E (Mar 2026)
Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo
News: 4 BI events in 12 mo (of 8 tracked, 2 types) · +0% YoY · Top themes: M&A
Audience (LinkedIn): 9k LinkedIn followers — 3.2% of this cohort's audience
Activity (LinkedIn): 2 awards announced in 12 mo
Funding rounds
- Mar 2026Series E$505M
- Sep 2024Series D$370M
Founders & team
Investors
Venrock, Fairmont, TCG Crossover, VenBio, Foresite Capital, Third Rock Ventures
Tech stack
CloudflareCloudflare Bot ManagementDreamhostGoogle Font ApiHttp/3Jquery
#4
Series D · San Diego, California · founded 2016 · 45 employees$70Mraised▾
Series D · San Diego, California · founded 2016 · 45 employees
Developer of non-invasive cancer detection methods. It offers a 5-hydroxymethylcytosine-based epigenomic platform and cell-free DNA-based assays to measure biological changes in cells and detect cancers with high mortality rates when they respond best to treatment.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Moat
top 22%Funding
top 36%Market
top 50%Talent
bottom 49%Global
bottom 36%Moat: Editorial + unicorn rating 8/10 · Soonicorn
Funding: Raised $70.0M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) · Last round Series D (May 2026)
Market: 45 employees (top 39% of Life Sciences)
Audience (LinkedIn): 6k LinkedIn followers — 2.3% of this cohort's audience
Funding rounds
- May 2025Series C$21.8M
- May 2021Series C$70M
Founders & team
Investors
Pathology Asia Holdings
#5
Series B · San Diego, California · founded 2003 · 54 employees$109Mraised▾
Series B · San Diego, California · founded 2003 · 54 employees
Developer of therapeutic solutions for the treatment of multiple diseases based on protein degradation technology. The company has developed a protein degradation entity that mainly focused on molecular glue degraders that destroy proteins linked to disease. These degraders can be classified as heterobifunctional that solve critical problems.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 23%Moat
top 28%Talent
top 28%Patents
top 39%Innovation
top 44%Partners
top 45%Funding: Raised $109M across 2 rounds · 2 rounds over 6 yrs (0.3/yr) · Last round Series B (Apr 2026)
Moat: Editorial + unicorn rating 8/10 · IP moat: 25 patents · Soonicorn
Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
Audience (LinkedIn): 9k LinkedIn followers — 3.3% of this cohort's audience · 78 engagements/post (2.5× cohort median)
Hiring (LinkedIn): 5 hiring posts in 12 mo (public) · momentum +5 · hiring: Director Clinical Operations, Director, Analytical Development, CMC
Funding rounds
- Apr 2026Series B$100M
- Dec 2020Series A$109M
Founders & team
Investors
Deerfield, Longwood Fund, Alexandria, Dana Farber, Regeneron Ventures
Tech stack
Amazon Web ServicesAstraCore-JsElementorHstsHttp/3
#6
Series C · San Diego, California · founded 2018 · 94 employees$224Mraised▾
Series C · San Diego, California · founded 2018 · 94 employees
Provider of genomic-based personalized pluripotent stem cell therapy. It offers regenerative cell treatment like dopaminergic neurons for Parkinson's disease and other neurological disorders. It maintains the genetic-based quality control to avoid the mutation of cells used for therapy.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Funding
top 17%Patents
top 23%Moat
top 28%Innovation
top 33%Growth
top 35%News
top 45%Funding: Raised $224M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) · Last round Series C (Nov 2025)
Patents: 57 patents matched (strict assignee match) · 51 filings since 2022 vs 6 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 8/10 · IP moat: 57 patents · Soonicorn
Audience (LinkedIn): 13k LinkedIn followers — 4.9% of this cohort's audience
Funding rounds
- Nov 2025Series C$115M
- Dec 2022Conventional Debt$40M
- May 2022Series B$147.5M
- Apr 2020Series A$70M
Founders & team
Investors
Orbimed, Arch Venture Partners, Frazier Healthcare Partners, Domain Associates, S32, Google Ventures
Tech stack
CloudflareCloudflare Bot ManagementCore-JsGeneratepressGeneratepress Gp PremiumGodaddy
#7
Series B · San Diego, California · founded 2020 · 14 employees$259.6Mraised▾
Series B · San Diego, California · founded 2020 · 14 employees
Provider of the drug for the treatment of oncology and autoimmune disorders. The company is involved in drug design and development based on small molecules.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 20%Patents
top 21%Innovation
top 23%Moat
top 26%News
bottom 42%Global
bottom 42%Funding: Raised $260M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) · Last round Series B (Nov 2025)
Patents: 133 patents matched (strict assignee match) · 133 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Innovation: 133 patents (top 21% of patent-holders) · 133 filings since 2022 vs 0 in 2017-21
Audience (LinkedIn): 9k LinkedIn followers — 3.4% of this cohort's audience
Hiring (LinkedIn): 3 hiring posts in 12 mo (public) · momentum +3 · hiring: Principal Programmer, Statistical Programming, Director/Senior Director, Medical Affairs
Funding rounds
- Nov 2025Series B$84.2M
- Dec 2023Series B$100M
- Mar 2021Series A$71M
Investors
Cormorant Asset Management, Orbimed, Vivo Capital, Colt Ventures, Plaisance Capital Management, H&D Asset Management
#8
Public · San Diego, California · founded 2011 · 7 employees$39.9Mraised▾
Public · San Diego, California · founded 2011 · 7 employees
Modifying lipid-signaling pathways to improve cancer treatments. This clinical-stage pharmaceutical manufacturing company focuses on oncology and endocannabinoid modulation. They develop treatments for conditions like cancer anorexia-cachexia syndrome, utilizing CBD, FABP5 inhibitors, and synthetic cannabinoids. Their pipeline includes ART27.13, ART26.12, and ART12.11. They aim to restore vitality and daily function in patients. The company is involved in medical innovation and cancer research, striving to improve the lives of those facing limited options. They are exploring novel non-opioid treatments for persistent pain and addressing stress-induced depression and anxiety symptoms.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 17%Growth
top 20%News
top 23%Product
top 24%Innovation
top 43%Talent
top 46%Funding: Raised $39.9M across 13 rounds · 13 rounds over 8 yrs (1.6/yr) · Last round Post IPO (Mar 2026)
Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo
News: 8 BI events in 12 mo (of 19 tracked, 6 types) · +700% YoY · 2 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 2k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. AI Leader ScienceMachine) announced in 12 mo
Funding rounds
- Mar 2026Post IPO$11M
- Jan 2026Post IPO$500K
- Oct 2025Post IPO$3.7M
- Aug 2025Post IPO$9.5M
Founders & team
Investors
National Cancer Institute
Tech stack
Apache Http ServerBootstrapFancyboxGodaddyGoogle AnalyticsGoogle Font Api
#9
Series D · San Diego, California · founded 2021$195Mraised▾
Series D · San Diego, California · founded 2021
Developer of antibody-based therapies targeting tumor-specific antigens for cancer treatment. The company focuses on advancing antibody-based therapeutics to address unmet medical needs. It refines a chemistry platform while developing targeted radionuclide therapeutics. The company evaluates companion radiodiagnostics for use with other types of targeted cancer therapeutics.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 16%Moat
top 40%Global
top 45%Market
bottom 49%Talent
bottom 49%Funding: Raised $195M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series D (Nov 2025)
Moat: Soonicorn · 10 curated direct competitors tracked
Global: Investors from 3 countries beyond United States
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Nov 2025Series D$120M
- Dec 2024Series C$75M
Founders & team
Investors
Yosemite, Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, Merck
#10
Series B · San Diego, California · founded 2017 · 7 employees$28.3Mraised▾
Series B · San Diego, California · founded 2017 · 7 employees
Alume Biosciences is developing a proprietary nerve illumination technology. The technology is claimed to enable the surgeons to view the nerves and reduce the damage to the nerves during surgical procedures.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 795 LinkedIn followers
Activity: 1 awards announced in 12 mo
Funding rounds
- Mar 2026Series B$2.2M
- Oct 2025Series B$6.9M
- Jan 2025Grant (prize money)$3.4M
- Sep 2023Grant (prize money)$1.8M
Founders & team
Investors
NIH, HHS, ALMA Life Sciences, BioBrit
Tech stack
BootstrapFont AwesomeGoogle Code PrettifyGoogle WorkspaceHttp/3Jquery
#11
Series B · San Diego, California · founded 2017 · 9 employees$46.8Mraised▾
Series B · San Diego, California · founded 2017 · 9 employees
Primmune Therapeutics is developing immunotherapies for treating cancer. They are developing a small molecule (orally administered) which is a toll-like receptor 7 (TLR7) agonist (an endosomal innate immune sensor capable of detecting single-stranded ribonucleic acid) helps in systemic activation of innate immunity. It gets expressed on plasmacytoid dendritic cells.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 21%Talent
top 28%Product
top 35%Innovation
top 38%Moat
top 39%Tech
bottom 40%Funding: Raised $46.8M across 8 rounds · 8 rounds over 6 yrs (1.3/yr) · Last round Series B (Jan 2026)
Talent: Analyst team rating 4/5 · 4 named leaders on record · 4 C-suite/founder profiles curated
Product: 3 distinct product lines · Company stage: Series B
Funding rounds
- Jan 2026Series B$8.6M
- Nov 2021Series A$8.4M
- Jan 2021Series A$4M
- Oct 2020Series A$27.4M
Founders & team
Investors
CAM Capital, BioBrit, BioRock Ventures, Bioqube Ventures, Polaris Partners, Samsara BioCapital
Tech stack
WordpressMysqlPhpDownload MonitorContact Form 7Yoast Seo
#12
Funding Raised · San Diego, California · founded 2014 · 4 employees$19.4Mraised▾
Funding Raised · San Diego, California · founded 2014 · 4 employees
Data-driven drug discovery using multi-omics, AI, and disease models. The company is transforming drug discovery by applying high-throughput multi-omics data, AI/machine learning, network analyses, and disease models to identify novel targets and mechanisms. Their LEADS® platform combines high-throughput screening, multi-omics data, AI, and network analyses to accelerate the discovery of first-in-class therapeutics. They focus on areas with high clinical unmet need, including neurology, oncology, and genetic diseases. By leveraging advances in metabolomics technologies and computational data analysis, they study diseases and compounds at an unprecedented level of biomolecular detail. This approach enables superior predictivity and facilitates the development of innovative medicines. The company collaborates with leading groups to explore therapeutic areas, offering a data-driven approach to advance drug discovery efforts.
Fliar Intelligence Index™ 13how this company ranks against its industry peers
Funding
top 28%AI
top 45%Global
bottom 29%Tech
bottom 26%Market
bottom 16%Funding: Raised $19.4M across 13 rounds · 13 rounds over 5 yrs (2.6/yr) · Last round Grant (prize money) (Mar 2026)
AI: Product described with: machine learning
Global: Single-market focus (United States)
Audience (LinkedIn): 524 LinkedIn followers
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. Ono Pharmaceutical Co., Ltd.) announced in 12 mo
Funding rounds
- Mar 2026Grant (prize money)—
- Dec 2025Grant (prize money)—
- May 2025Grant (prize money)$318.3K
- Sep 2024Grant (prize money)$2.2M
Investors
NIH, NIDCR, NINDS, HHS, NIGMS, National Cancer Institute
Funding & investor landscape
$29.3Btotal disclosed funding
496companies funded
2,087disclosed rounds
6rounds last 90 days
Most active investors
Notable founders
Fred Manby
Co-Founder & CTO · Iambic Therapeutics
Thomas Miller
Co-Founder & CEO · Iambic Therapeutics
Mark McKenna
Founder & CEO · Mirador
Ken Song
CEO · Candid Therapeutics
Dave Mullarkey
Chief Executive Officer · ClearNote Health
Philip Chamberlain
Co-Founder & CEO · Neomorph
Scott Armstrong
Co-Founder · Neomorph
Damien Mcdevitt
President · Aspen Neuroscience
Greg Gorgas
CEO & President · Artelo Biosciences
Dave Johnson
Founder & CEO · Solve Therapeutics
Mike Whitney
Scientific Founder and VP of Discovery · Alume Biosciences
Quyen Nguyen
Co-Founder & CEO · Alume Biosciences
Prism market signals · United States · country-scoped Prism corpus, 1,465,538 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
research sentiment over time
200820162026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and steady — the enthusiastic (strongly-positive) share moved 44% → 42% across 2008–2026.
top research entities
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
leading researchers
Stylianos Chatzimanolis · TARIK DEDOVIC · KATH-RYN ANN F. HANKINS · Christoforos Pavlou · Giannis Bolanakis · Ashley R Tetens · Tyler Findlay · Jordyn Craig-Schwartz
▲
Breakthroughs2,038 · 33%
▼ 41%→30% share
▼0.7× share momentum0 median citations71% since 2021mostly empirical
Gene-focused breakthrough research is surging — papers rose from 33 to 164, even as breakthroughs' overall field-share fell from 41% to 30%.
rising sub-themes (early→recent)
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
Newly emergingIdentification (biology) 0→18 · Function (biology) 0→18 · Reporter gene 0→16
Landmark U1 snRNP regulates cancer cell migration and invasion in vitro · 7,224 cites
◆
Advancements2,118 · 34%
▲ 29%→35% share
▲1.2× share momentum0 median citations80% since 2021mostly empirical
Cell culture and fermentation advancements are intensifying simultaneously — papers jumped from 3→62 and 2→54 respectively.
rising sub-themes (early→recent)
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
Newly emergingIdentification (biology) 0→27 · Probiotic 0→24 · Cultivar 0→23
Landmark Using Deep Learning for Image-Based Plant Disease Detection · 4,262 cites
▼
Concerns1,006 · 16%
▼ 17%→15% share
▼0.9× share momentum0 median citations73% since 2021mostly empirical
Antibiotic resistance concern is rising sharply — papers tripled from 15 to 45 across U.S. biotechnology institutions.
rising sub-themes (early→recent)
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Newly emergingQuality (philosophy) 0→27 · Animal health 0→14 · Integrated pest management 0→13
Landmark The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate · 8,812 cites
RESEARCH HOTSPOTS · United States
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston351 · +0.52
New York319 · +0.47
SF Bay Area235 · +0.57
Philadelphia115 · +0.60
San Diego101 · +0.59
Seattle95 · +0.46
Chicago95 · +0.57
Los Angeles93 · +0.61
Pittsburgh65 · +0.54
Ann Arbor65 · +0.58
PATENT SIGNAL · United States
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
457,918 filings8,000 assigneespeak 51616/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Genentech18350
- UNIV California18093
- Regeneron Pharma16106
- Amgen10600
- Monsanto Technology9821
- UNIV Pennsylvania8586
- Harvard College7497
- UNIV Texas7427
Common questions
How many Life Sciences companies are there in San Diego, United States?
Radar tracks 847 indexable Life Sciences companies headquartered in San Diego, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in San Diego, United States?
The Life Sciences companies in San Diego, United States on this list have raised a combined $29.3B in disclosed equity funding across 496 funded companies.
Which is the highest-funded Life Sciences company in San Diego, United States?
Halozyme is the highest-funded Life Sciences company in San Diego, United States, with $1.3B in disclosed equity funding.
How many Life Sciences companies in San Diego, United States are funded?
496 of the 847 Life Sciences companies in San Diego, United States on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in San Diego, United States?
2 Life Sciences companies in San Diego, United States on this list are valued at $1B or more.
Who are the top investors in San Diego, United States Life Sciences companies?
The most active investors in San Diego, United States Life Sciences companies on this list include HHS, JLABS, Orbimed, Domain Associates, Venrock.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.